Tango Therapeutics, Inc. (TNGX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
the bull case· 2
247
managers reporting a position in thirteen f filings
13fJun 30 '26+24.55%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 4
8 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized4
of the funds on file reporting a position in the company
n-portas of Jun 30 '260.84%
of State Street SPDR S&P Biotech ETF assets, largest fund weight on file
n-portJun 30 '265 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Of the 6 companies Tango Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
Tango Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 23.40 at 7:00 am ET, low 21.75 at 3:45 pm ET.
TNGX (Tango Therapeutics, Inc.) has 1 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
246 managers report a position worth $6.7B between them, and 31 of them hold 80% of it.